CATALYST PHARMACEUTICALS, INC.
At today's price, CATALYST PHARMACEUTICALS, INC. (CPRX) is priced for +4.0% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
- Catalyst Pharmaceuticals has agreed to be acquired by Angelini Pharma for $31.50 per share in cash, a roughly $4.1 billion deal signed May 6, 2026. At $31.38 the stock trades essentially at the takeout price, so the relevant question is deal completion, not standalone valuation. - The business itself is a profitable rare-disease specialty pharma. Q1 2026 revenue was $149.4 million, up 28%, on Firdapse for Lambert-Eaton myasthenic syndrome (up 18% to $98.9M) and Agamree for Duchenne muscular dy
Is CPRX overvalued? See what's priced in →
370 institutional managers reported holding CPRX in 13F filings for the quarter ended 2026-03-31. Together they hold about 82% of the company; the top 10 hold 45%. 44 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 8.0M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (5.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CPRX's share count grew 18.2% over the past five years even with $29.61M spent on repurchases. It pays no dividend. Cash returned over the past three years: $14.57M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at CPRX over the trailing three years. Absence is a fact about the company, not a signal. 16 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CPRX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-10 | +4.8% | -15.4% |
| 2023-11-09 | -4.1% | +19.4% |
| 2024-02-29 | +0.8% | -6.3% |
| 2024-05-09 | +3.4% | +4.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CPRX's latest 8-K filings: 2026-07-16 (items 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01); 2026-07-08 (items 5.02, 5.07); 2026-06-30 (items 8.01, 9.01); 2026-06-23 (items 8.01); 2026-05-11 (items 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.